Nature Clinical Practice Oncology
Angiogenesis as a Strategic Target for Ovarian Cancer Therapy CME

Disclosures

Release Date: February 12, 2008; Valid for credit through February 12, 2009
Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

Contents of This CME Activity
    To participate in this activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

    Antivascular agents that selectively target tumor angiogenesis are an emerging and important treatment option for patients with ovarian cancer. The current article reviews the state of the art and future directions for the use of these agents.

  1. Angiogenesis as a Strategic Target for Ovarian Cancer Therapy
    Whitney A. Spannuth, MD
    Anil K. Sood, MD
    Robert L. Coleman, MD

Go to Test Questions

 
Legal Disclaimer
The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Copyright © 2008 Medscape.

 
Medscape
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Specify the most promising receptor targeted by antivascular treatment
  2. Describe the efficacy and safety of treatments that target vascular endothelial growth factor
  3. Describe possible future antivascular treatments for ovarian cancer
  4. Identify biomarkers that may be helpful to follow the efficacy of antivascular treatment for ovarian cancer
Authors and Disclosures

Whitney A. Spannuth, MD
Disclosure: Whitney A. Spannuth, MD, has disclosed no relevant financial relationships.


Anil K. Sood, MD
Disclosure: Anil K. Sood, MD, has disclosed no relevant financial relationships.


Robert L. Coleman, MD
Disclosure: Robert L. Coleman, MD, has disclosed no relevant financial relationships.


Charles P. Vega, MD
Disclosure: Charles P. Vega, MD, has disclosed that he has served as an advisor or consultant to Novartis, Inc.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.